The survival rate of therapy with tumor necrosis factor-αinhibitors: main causes and drug substitution tactics
The paper gives data on the efficacy and safety of tumor necrosis factor-α(TNF-α) inhibitors used in first- and second-line therapy. It describes options to optimize treatment with TNF-αinhibitors in first-line therapy, by increasing the dose, which is accompanied by the greater effect only with inf...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2018-12-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/858 |
| Summary: | The paper gives data on the efficacy and safety of tumor necrosis factor-α(TNF-α) inhibitors used in first- and second-line therapy. It describes options to optimize treatment with TNF-αinhibitors in first-line therapy, by increasing the dose, which is accompanied by the greater effect only with infliximab; by changing the dose of concomitant disease-modifying antirheumatic drugs, primarily methotrexate (MTX), the use of which increases the probability of achieving the effect of TNF-αinhibitors, the magnitude of the effect rises with the larger doses of MTX or with its parenteral formulation. There are data on the effectiveness of switching from the first TNF-αinhibitor to the second TNF-αinhibitor or to a biologic agent with another mechanism of action. |
|---|---|
| ISSN: | 1996-7012 2310-158X |